InSeal Medical recently announced that it has received CE Mark approval for its InClosure large bore vascular closure device (VCD). The InSeal VCD provides an internal biodegradable membrane for sealing large cuts in blood vessels. The figures below show InSeal’s InClosure VCD, before (left) and after (right) biodegradation.
According to PRNewswire, the need for such a device is, at least partially, driven by the increased prevalence of transcatheter heart valve procedures, which involve the delivery of relatively large medical device through a patient’s blood vessels. While superior in some respects to open-heart surgical alternatives, these transcatheter procedures still require making a large puncture in a blood vessel in order to introduce the medical device. The InClosure device is aimed at addressing these punctures.
InSeal Medical, Ltd. is a subsidiary of E-Pacing, Inc., and is based in Caesarea, Israel.
